38 résultats
20190323594964Saunders 2019. New/New. <p><strong>Author:</strong> David M. Vail DVM MS DACVIM Oncology Douglas H. Thamm VMD DACVIM Oncology Julius M. Liptak BVSc MVetClinStud FACVSc DECVS DACVS</p><p><strong>Publisher:</strong> Saunders</p><p><strong>ISBN:</strong> 9780323594967</p><p><strong>Release Date:</strong> 2019</p><p><strong>Languages:</strong> English</p><p><strong>Binding:</strong> Hardcover</p><p><strong>Number Of Pages:</strong> 864</p><p><strong>Details:</strong> About the Author Dr. Vail has published over 120 peer-reviewed scientific manuscripts and 50 book chapters in the field of veterinary and comparative oncology. David is co-editor of the textbook Small Animal Clinical Oncology past North American Journal Editor for Veterinary and Comparative Oncology President of the Canine Comparative Oncology and Genomics Consortium CCOGC and a founding member of the Comparative Oncology Trials Consortium COTC. He is the past Chairman of the Scientific Advisory Boards for both the Morris Animal Foundation and the American College of Veterinary Internal Medicine Foundation. He has been honored as the recipient of both the Mark L. Morris Sr. Distinguished Research Award and the Pfizer Award for Veterinary Research Excellence.<br><br>Dr. Thamm received his bachelor’s and VMD degrees from the University of Pennsylvania. After finishing veterinary school he completed an Oncology Residency at the University of Wisconsin and was a researcher there for five additional years before joining the faculty at CSU in 2004.<br><br>Dr. Liptak was the founding President of the Veterinary Society of Surgical Oncology. In 2010 he was awarded the Stephen J. Withrow Award for Advancing the Art and Science of Surgical Oncology. In 2012 Dr. Liptak became an ACVS Founding Fellow in Surgical Oncology - one of four in Canada and less than 70 in the world. In 2020 Dr. Liptak was accepted as a RCVS Specialist in Surgical Oncology one of six in the world. In 2021 he became an ACVS Founding Fellow in Oral and Maxillofacial Surgery one of only ten in the world. His main interests center around maxillofacial surgery for oral tumors chest wall resection and reconstruction for rib tumors musculoskeletal oncology and include bone tumors and soft tissue sarcomas but also soft tissue tumors such as apocrine gland anal sac adenocarcinomas. Dr. Liptak is one of the pioneers in sentinel lymph node mapping and using patient-specific customized 3D-printed titanium implants for oncologic reconstructions.</p> Saunders hardcover
2012NOCT17-9781435492882-626Saunders 2012-11-27. Hardcover. New. 0x0x0. NEW TEXTBOOK SHIPS WITH EMAILED TRACKING FROM USA Saunders hardcover
2022550Cham (Switzerland), Springer, 2022. First and only edition. Softcover, 13 x 20,5 cm, (xv) 580 pp. Contents: The Pharmacist in Oncology and Hematology, Oncological Diseases, Hematological Diseases, Drugs Used in Chemotherapy, Immunotherapy, CAR-T Cells and Related Technology, Stem Cell Transplantation, Managing Issues: Tumor Lysis, Extravasation, Adverse Effects and Others, etc. With many contributors from Brazil, this guide aims to be a gold standard in oncopharmacology. From the editor: "This book fills an important gap in the professional's daily practice of both Oncology and Hematology. From the understanding of oncological and hematological diseases, drugs and protocols, to the administration of an oncology pharmacy, this book is an essential guide to supporting health professionals working or that intend to work in this area.This golden standard to practice is featured as a pocket guide easy to be carried around the hospital or clinic. The chapters cover topics such as support drugs; immunotherapy; CART-cells; chemotherapy for rheumatology, surgery and ICU; tumor lysis; extravasation; adverse effects; and stem cell transplantation. The content gathered in this volume is an invaluable resource not only to oncologic, clinical and hospital pharmacists, but also residents, postgraduate and undergraduate students."
2024__0323930522Elsevier Science Health Science 2024. Paperback. New. 7th pap/psc edition. 218 pages. 10.50x8.00x0.50 inches. Elsevier Science Health Science paperback
2024SONG0323930522Elsevier 2024-05-15. 7. paperback. Used: Good. 8.27x0.47x10.79. Buy with confidence. Excellent Customer Service & Return policy. Elsevier paperback
2024DADAX0323930522Elsevier 2024-05-15. 7. paperback. New. 8.27x0.47x10.79. Buy with confidence. Excellent Customer Service & Return policy. Elsevier paperback
2005Q-0721603599Saunders 2005-03-01. Paperback. New. In shrink wrap. Looks like an interesting title! Saunders paperback
2001Q-072167755XSaunders 2001-06-01. Hardcover. New. In shrink wrap. Looks like an interesting title! Saunders hardcover
2001DADAX072167755XSaunders 2001-06-01. 3. hardcover. New. 7.87x5.51x1.57. Buy with confidence. Excellent Customer Service & Return policy. Saunders hardcover
2011x-1447116054Springer-Verlag 2011. Paperback. New. 1st edition. 248 pages. 10.00x7.00x0.75 inches. Springer-Verlag paperback
2016AME_9781496333971kluwer 2016. 10th. Paperback. New/New. kluwer paperback
2003015011London: Kluwer Academic Publishers 2003. Fourth Edition. Cloth/Laminated Boards. Very Good/No d/j as Published. 4to - over 9¾" - 12" tall. Type: Book The book summarizes an evolving science and a rapidly changing medical practice. In this new millennium it now becomes possible to envision a much more diversified system of cancer research and treatment that will afford greater opportunities for patients. Some forms of cancer biotherapy use the strategy of tumour stabilization and control through continued biological therapy akin to the use of insulin in the treatment of diabetes. This textbook illustrates new methods of thinking and new strategies for control of cancer. It is always difficult to move from past dogma to future opportunity but this fourth edition of "Principles of Cancer Biotherapy" illustrates why it is so important to the patients for researchers and clinicians to explore and apply these new opportunities in cancer biotherapy.688pp. Kluwer Academic Publishers hardcover
2021DADAX0880910674Academy of Nutrition and Dietetics 2021-05-05. 2. paperback. New. 7.99x10.00x1.85. Buy with confidence. Excellent Customer Service & Return policy. Academy of Nutrition and Dietetics paperback
2021SONG0880910674Academy of Nutrition and Dietetics 2021-05-05. 2. paperback. Used: Good. 7.99x10.00x1.85. Buy with confidence. Excellent Customer Service & Return policy. Academy of Nutrition and Dietetics paperback
2021V03071B00118UAcademy of Nutrition and Dietetics 2021-05-05. paperback. Like New. 11x1x8. No highlighting. Very minimal wear. Academy of Nutrition and Dietetics paperback
2021V05158C00066UAcademy of Nutrition and Dietetics 2021-05-05. paperback. Like New. 11x1x8. No highlighting. Very minimal wear. Academy of Nutrition and Dietetics paperback
20101-1610723961Mometrix Media Llc 2010. Paperback. New. flc crds edition. 243 pages. 11.00x8.40x0.40 inches. Mometrix Media Llc paperback
20101-1610723953Mometrix Media LLC 2010. Paperback. New. 144 pages. 8.40x6.20x0.20 inches. Mometrix Media LLC paperback
20181-0880910674American Dietetic AssociationU.S. 2018. Paperback. New. 690 pages. 11.10x8.62x1.81 inches. American Dietetic Association,U.S. paperback
20064000935882006 2006. attention textes en anglais. Expressions of a woman's cancer journey. gros volume broché regroupant des centaines d'oeuvres d'art en couleur ( peintures photos montages.) et superbe ouvrage de collection. édition originale de 2005. Une initiative originale pour donner la parole aux patients. En 2004 Lilly Oncologie organise le premier concours artistique international Lilly oncology on canvas. L'art pour donner un sens à son expérience du cancer. Destiné en premier lieu à faire prendre conscience des défis et des succès remportés sur la vie par les personnes atteintes d'un cancer ce concours permet de collecter des fonds pour les associations caritatives engagées dans la lutte contre le cancer. Ce premier concours (l'expérience fut renouvelée en 2006) a connu un véritable succès : plus de 400 œuvres de femmes atteintes dun cancer du sein de soignants ou de proches ont été recueillies dans 23 pays à travers le monde. Aujourdhui cette riche collection voyage partout dans le monde et touche les coeurs et les esprits de chacun. RARE et en bon état; l'intérieur est en en excellent état sans annotations ni déchirures bien frais; la couverture et les toutes premières pages sont légèrement cornées
2003551São Paulo, Lemar and Tecmedd, 2003. Hardcover, 18 x 24 cm, 368 pp. Printed on glossy paper, illustrated. 27 chapters about "The Classification of MDS and myeloproliferative disorders in children", "Pitfalls in cyto-histology of pediatric MDS/JMML", "Molecular biology of hematopoietic cells in MDS: an evolutionary perspective", "The importance of bone marrow histology in MDS" and many other matters. Various contributors. From the editors: "The last decade has seen a surge of interest in pediatric myelodysplastic diseases and a number of initiatives to improve registration,diagnosis, and management have been launched. An increasing number of publications have appeared but no book has as yet compiled the many aspects of myelodysplastic diseases in children.This book has contributions from the major researchers and groups involved in the study of myelodysplasia and myeloproliferative disorders in children. It is composed of three introducing chapters on classification and epidemiology followed by detailed discussion of the many aspects of MDS and JMML. The last chapters present the experiences from a number of study groups worldwide describing their achievements in the study of this intriguing group of diseases. The book reflects out current knowledge on myelodysplastic and myeloproliferative disorders including some controversies. In a field moving rapidly towards new accomplishments discrepancies in interpretation of the data will invariably exist.It has been a pleasure to collaborate with this distinguished group of authors. We hope hematologists, pediatric oncologists, and laboratorial professionals will find the book useful in clinical practice and an inspiring basis for further research."
2003014591London: Kluwer Academic Publishers 2003. Cloth/Laminated Boards. Like New/No d/j as Published. 8vo - over 7¾" - 9¾" tall. Type: Book Distant metastases are the main cause of cancer-related death. The onset of the metastatic process can now be assessed in cancer patients by the use of immunocytochemical and molecular methods that allow the identification of disseminated carcinoma cells in regional lymph nodes peripheral blood or distant organs. There is increasing evidence that the detection and characterization of tumor cells present in bone marrow or peripheral blood can provide clinically important information. In this book leading experts in the area of micrometastasis research provide an overview that summarizes the current state of research on micrometastatic disease in patients with solid tumors. In each chapter the technical aspect as well as clinical relevance of micrometastasis detection is discussed. The book addresses basic researchers as well as clinicians involved in the treatment of cancer patients.189pp. Kluwer Academic Publishers hardcover
2010SONG1848163126Brand: Imperial College Press 2010-09-01. 1. hardcover. Used: Good. 6.10x0.80x9.00. Buy with confidence. Excellent Customer Service & Return policy. Brand: Imperial College Press hardcover
2010DADAX1848163126Brand: Imperial College Press 2010-09-01. 1. hardcover. New. 6.10x0.80x9.00. Buy with confidence. Excellent Customer Service & Return policy. Brand: Imperial College Press hardcover
2002014692London: Kluwer Academic Publishers 2002. Cloth. Like New/Like New. 8vo - over 7¾" - 9¾" tall. Type: Book Hepatocellular carcinoma HCC and cholangiocarcinoma CC both increasing in incidence have become a major topic of basic and clinical research as well as clinical practice in hepatology. Experts in the field update the current concepts on the carcinogenesis of HCC and CC such as genetic alterations in the pathways of cell cycle and apoptosis regulation the hypothesis of dedifferentiation of hepatocytes to the malignant phenotype vs that of activation of hepatic progenitor cells incapable of maturation maturation arrest hypothesis. In spite of an increasing number of genetic alterations described in human HCC as well as cell regulatory pathways tested in experimental HCC models the key hits causing progression of the cell cycle in imbalance with apoptosis tissue invasive growth and metastatic potential of cell clones still remain elusive. Very powerful genomic and proteomic techniques are promising insights into the carcinogenesis of liver malignancies that will allow more efficient therapeutic strategies. The current concepts on risk profiling surveillance of risk groups and therapeutic strategies are evidence-based for HCC and less detailed for CC. Surveillance of risk groups improves detection of liver tumours in curable stages. Best strategies for curative treatment of HCC use neoadjuvant antitumour therapies before liver transplantation and a role is emerging for living donor-related liver transplantation. New palliative therapies for HCC are in the experimental stage with biological response modifiers including angiogenesis inhibitors and entering phase II clinical trials with the alpha-fetoprotein derived vaccines.211pp.N.B.Slight fade mark to base of d/j spine. Kluwer Academic Publishers hardcover
